Bacterial sepsis-induced decrease in lung vascular reactivity to 9,11-dideoxy-11a9a-epoxymethano-prostaglandin F2...

Area of Science:

• Cardiovascular Physiology
• Sepsis Pathophysiology
• Prostanoid Signaling

Background:

• Sepsis can lead to significant alterations in cardiovascular function.
• Cyclooxygenase (COX) products, including thromboxane A2 (TXA2), play a role in vascular tone.
• The impact of sepsis-induced COX products on pulmonary vascular reactivity to TXA2 mimics is not fully understood.

Purpose of the Study:

• To investigate if sepsis-associated increases in cyclooxygenase products affect the pulmonary vascular response to the thromboxane A2 mimic, U46619.
• To determine the role of TXA2 in sepsis-induced alterations in pulmonary vascular reactivity.

Main Methods:

• Sepsis was induced in rats via cecal ligation and puncture.
• Pulmonary vascular reactivity to U46619 and angiotensin II was assessed.
• Levels of immunoreactive thromboxane B2 (iTXB2) were measured in pulmonary effluent.
• The effect of ibuprofen pretreatment on these parameters was evaluated.

Main Results:

• Sepsis significantly increased pulmonary iTXB2 levels (156.8%).
• Pulmonary vascular reactivity to U46619 was significantly decreased in septic rats compared to controls.
• This decreased reactivity was specific to the TXA2 pathway, as responses to angiotensin II were unaffected.
• Sham surgery did not alter iTXB2 levels or vascular reactivity.
• Ibuprofen pretreatment prevented the sepsis-associated increase in iTXB2 and the decrease in vascular reactivity.

Conclusions:

• Sepsis-induced increases in thromboxane A2 and/or other cyclooxygenase products alter pulmonary vascular response to the TXA2 mimic U46619.
• COX products play a critical role in mediating sepsis-induced changes in pulmonary vascular reactivity.
• Targeting COX pathways may offer a therapeutic strategy for managing sepsis-related cardiovascular complications.